Rosenblum Mark J
Known title: Exec VP Finance, CFOCIK: 0001329154
Rosenblum Mark J's purchase track record
How the stock did after each of Rosenblum Mark J's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since March 3, 2022
Stock higher 6 months later
0%
3 months: 67%
Median 6-month return
-44.8%
3 months: +6.4%
Beat the S&P 500
0%
median -42.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/20/2025 | DCOY | $16K | +6.4% | -28.6% | +13.9% |
| 5/31/2022 | DCOY | $5K | +14.4% | -56.4% | -4.2% |
| 3/3/2022 | DCOY | $30K | -53.4% | -44.8% | -9.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DCOY | ▲ Buy | Grant | 9,682 | $0 | 8/31/2026 | View on chart |
| DCOY | ▲ Buy | Open Market | 20,000 | $16K | 11/20/2025 | View on chart |
| DCOY | ▲ Buy | Grant | 6,432 | $0 | 2/13/2023 | View on chart |
| DCOY | ▲ Buy | Grant | 8,000 | $0 | 1/3/2023 | View on chart |
| DCOY | ▲ Buy | Grant | 7,314 | $13K | 11/3/2022 | View on chart |
| DCOY | ▲ Buy | Open Market | 28,000 | $5K | 5/31/2022 | View on chart |
| DCOY | ▲ Buy | Grant | 10,000 | $2K | 5/3/2022 | View on chart |
| DCOY | ▲ Buy | Open Market | 76,246 | $30K | 3/3/2022 | View on chart |
| DCOY | ▲ Buy | Grant | 7,787 | $6K | 11/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
DCOY Reports Preclinical Data for Once-Weekly Dosing
Decoy Therapeutics released preclinical data supporting a once-weekly intranasal dosing schedule for its DCOY-CoV program. The company is also scheduled to present at The Small Cap Showcase investor conference. These updates provide context for the stock's current trading levels, which sit near significant support.
DCOY Reports Preclinical Data for Once-Weekly Dosing. Decoy Therapeutics released preclinical data supporting a once-weekly intranasal dosing schedule for its DCOY-CoV program. The company is also scheduled to present at The Small Cap Showcase investor conference. These updates provide context for the stock's current trading levels, which sit near significant support.